Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Expert Analyses of the following article:

Genentech Set Back by Cancer-Drug Study

Source: online.wsj.com
Donald FlemingOctober 9, 2008
Beta trial negative, but is it truely blinded
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.
Beta trial implies that Avastin adds to the effectiveness of the other Genentech drug, Tarceva There is an attempt to change treatment gudelines in second line non small treatment
October 8, 2008
Avastin/Tarceva/Roche/OSI/Genentech: So much for "synergy" in lung cancer
Author: GLG Expert Contributor
The primary goal was improved survival- NOT REACHED!!

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-11-21T13:45:47.600